Press Releases
Calidi is at the forefront of the genetic medicine revolution in cancer and other indications
Read the Latest
Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors
SAN DIEGO, CALIF. — June 27, 2024 – Calidi Biotherapeutics, Inc. (NYSE American: CLDI or…
Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13
SAN DIEGO–(BUSINESS WIRE)–Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology…
Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi’s Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors
Calidi’s best-in-class, novel systemic targeted virotherapy program (RTNova) aims to provide a feasible solution to…
Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting
– NeuroNova (CLD-101) Phase 1 update highlights enrollment progress, safety and feasibility in delivering up…
Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
SAN DIEGO–(BUSINESS WIRE)–Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology…
Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results
Three upcoming posters, including an update from ongoing Phase 1 trial of Calidi’s CLD-101 program,…